- Home
- DRMA vs BGMS Comparison
DRMA vs BGMS Comparison
Compare DRMA & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRMA | BGMS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 5.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DRMA | BGMS |
|---|---|---|
| Price | $1.35 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 146.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.74 |
| 52 Week High | $7.33 | $6.70 |
Technical Indicators
Market Signals| Indicator | DRMA | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 45.25 |
| Support Level | $1.21 | $0.98 |
| Resistance Level | $2.29 | $1.06 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 38.74 | 58.21 |
Price Performance
Historical ComparisonAbout DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.